NYSE - Delayed Quote USD

Dr. Reddy's Laboratories Limited (RDY)

Compare
79.51 +0.03 (+0.04%)
At close: September 25 at 4:00 PM EDT
Loading Chart for RDY
DELL
  • Previous Close 79.48
  • Open 79.67
  • Bid 79.55 x 900
  • Ask --
  • Day's Range 79.39 - 80.13
  • 52 Week Range 63.72 - 84.46
  • Volume 99,549
  • Avg. Volume 209,141
  • Market Cap (intraday) 13.344B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 19.93
  • EPS (TTM) 3.99
  • Earnings Date Oct 25, 2024 - Oct 29, 2024
  • Forward Dividend & Yield 0.48 (0.60%)
  • Ex-Dividend Date Jul 30, 2024
  • 1y Target Est 85.80

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

www.drreddys.com

27,048

Full Time Employees

March 31

Fiscal Year Ends

Recent News: RDY

View More

Research Reports: RDY

View More

Performance Overview: RDY

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RDY
14.94%
S&P BSE SENSEX
18.82%

1-Year Return

RDY
21.12%
S&P BSE SENSEX
30.01%

3-Year Return

RDY
26.96%
S&P BSE SENSEX
42.94%

5-Year Return

RDY
113.78%
S&P BSE SENSEX
122.41%

Compare To: RDY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RDY

View More

Valuation Measures

Annual
As of 9/25/2024
  • Market Cap

    13.34B

  • Enterprise Value

    12.58B

  • Trailing P/E

    19.94

  • Forward P/E

    21.37

  • PEG Ratio (5yr expected)

    4.57

  • Price/Sales (ttm)

    3.84

  • Price/Book (mrq)

    3.76

  • Enterprise Value/Revenue

    3.64

  • Enterprise Value/EBITDA

    11.82

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.26%

  • Return on Assets (ttm)

    10.93%

  • Return on Equity (ttm)

    20.59%

  • Revenue (ttm)

    288.51B

  • Net Income Avi to Common (ttm)

    55.58B

  • Diluted EPS (ttm)

    3.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    94.63B

  • Total Debt/Equity (mrq)

    10.41%

  • Levered Free Cash Flow (ttm)

    17.53B

Research Analysis: RDY

View More

Company Insights: RDY

People Also Watch